"Methotrexate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
| Descriptor ID |
D008727
|
| MeSH Number(s) |
D03.633.100.733.631.192.500
|
| Concept/Terms |
Methotrexate Sodium- Methotrexate Sodium
- Sodium, Methotrexate
- Methotrexate, Sodium Salt
- Methotrexate, Disodium Salt
|
Below are MeSH descriptors whose meaning is more general than "Methotrexate".
Below are MeSH descriptors whose meaning is more specific than "Methotrexate".
This graph shows the total number of publications written about "Methotrexate" by people in this website by year, and whether "Methotrexate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 5 | 6 |
| 1999 | 0 | 3 | 3 |
| 2000 | 3 | 0 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 4 | 4 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 3 | 4 | 7 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 3 | 4 |
| 2008 | 1 | 4 | 5 |
| 2009 | 1 | 7 | 8 |
| 2010 | 1 | 5 | 6 |
| 2011 | 1 | 5 | 6 |
| 2012 | 0 | 4 | 4 |
| 2013 | 5 | 3 | 8 |
| 2014 | 2 | 0 | 2 |
| 2015 | 3 | 7 | 10 |
| 2016 | 1 | 5 | 6 |
| 2017 | 5 | 6 | 11 |
| 2018 | 5 | 2 | 7 |
| 2019 | 4 | 2 | 6 |
| 2020 | 2 | 5 | 7 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 6 | 7 |
| 2023 | 2 | 4 | 6 |
| 2024 | 5 | 4 | 9 |
| 2025 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methotrexate" by people in Profiles.
-
Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. Oncologist. 2025 Jun 04; 30(6).
-
High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi. JCO Glob Oncol. 2025 Mar; 11:e2400591.
-
Intrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income Country. JCO Glob Oncol. 2025 Mar; 11:e2400450.
-
Infantile myofibromatosis: Small bumps pose big problems. J Neonatal Perinatal Med. 2025 Mar; 18(2):179-183.
-
Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Pediatr Blood Cancer. 2024 Oct; 71(10):e31213.
-
Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene. Pediatr Blood Cancer. 2021 08; 68(8):e29036.
-
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage. Pediatr Blood Cancer. 2020 09; 67(9):e28334.
-
Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia. Leuk Lymphoma. 2020 11; 61(11):2771-2774.
-
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020 05 04; 10(5):49.
-
Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma. Pediatr Blood Cancer. 2020 04; 67(4):e28123.